Cancer News
Everolimus to cover unmet health care need
The agent everolimus showed real promise in treating patients with nonfunctional neuroendocrine tumors of lung or gastrointestinal origin, a new study reveals.
A constipation drug extends survival in advanced cancer patients
Methylnaltrexone, a drug approved to treat opioid-induced constipation showed promise when administered to advanced cancer patients, a new study reveals.
FDA expands the use of melanoma drug Yervoy
Patients with stage III melanoma with a high risk of recurrence after surgery can now be treated with Yervoy as the FDA has expanded the use of this melanoma drug.
Surgery: a treatment option for more pancreatic cancer patients
Pancreatic cancer patients who undergo complex tumor removal operations survive longer, according to a Mayo Clinic gastrointestinal surgeon.
Viral immunotherapy gets EU approval for melanoma
A viral immunotherapy got approved by EU regulators for the treatment of melanoma patients.
New treatment option approved for soft-tissue sarcoma
U.S regulators approved trabectedin (Yondelis) for the treatment of certain types of unresectable or metastatic soft-tissue sarcomas.
Lenvima gives hope to differentiated thyroid cancer patients
Lenvatinib (Lenvima) benefited metastatic differentiated thyroid cancer patients across all common sites of metastasis, scientists reported.
Breast Conservation: an option for more breast cancer patients
Breast conservation therapy should be suggested as a treatment option to breast cancer patients with larger tumors, researchers reported.
Positive results of lenvatinib in advanced thyroid cancer
Data from a phase 3 trial and various sub-analyses show that lenvatinib improved progression-free survival in patients with differentiated thyroid cancer.
FDA approves advanced pancreatic cancer treatment
The combination of irinotecan liposome injection with fluorouracil and leucovorin has been approved by the FDA for the treatment of metastatic pancreatic cancer.
The important role of nurses in radiation oncology
Advance practice nurses can offer high-quality, cost-effective care in high-risk patients who receive chemo-radiation therapy for head and neck cancer, a new research shows.
Cervical cancer: less side effects with specialized radiation therapy
Cervical cancer patients had less bowel side effects when treated with image-guided intensity-modulated radiation therapy, a new study reveals.
Treatment for less toxicity in locally advanced esophageal cancer
Radiation therapy that targets only the involved lymph nodes regions results in less toxicity without affecting overall survival rates in esophageal cancer patients.
Combining immunotherapy with radiation therapy for melanoma patients
A subset of patients with metastatic melanoma benefited from a combined treatment of immunotherapy and palliative radiation therapy, a new research reveals.
A more convenient treatment for low-risk prostate cancer patients
A shorter radiation therapy schedule was equally beneficial as a longer treatment schedule for some men with low-risk prostate cancer.
Steroid use for less pain flare in patients with bone metastasis
Cancer patients with painful bone metastases experienced fewer and less severe radiation-induced pain flare episodes with the steroid dexamethasone.
Less lung toxicity in lung cancer patients with radiation therapy
Non-small cell lung cancer patients who received intensity modulated radiation therapy had lower occurrence of severe pneumonitis, a secondary analysis reported.
New test help testicular cancers choose between monitoring and chemo
A new test can detect for which testicular cancer patients surveillance would be the best choice, sparing them from the side-effects of chemotherapy.
Some breast cancer patients may not benefit from Herceptin
The analysis of a trial revealed that HER2-positive breast cancer patients benefited more from receiving chemotherapy alone than chemotherapy plus trastuzumab.
CT scan follow-up could prevent lung cancer's return
Patients with lung cancer patients survived longer if their management included a follow-up program based on computer tomography (CT) of the chest, a new study shows.
Nivolumab gets expanded approval to treat advanced lung cancer
U.S. regulators approved nivolumab for the treatment of patients with non-squamous non-small cell lung cancer.
Dietary habits of cancer survivors linked to their long-term health
A new study sheds light on the dietary habits of cancer survivors pointing out the need for dietary interventions in order to prevent a variety of health problems.
Surgical resection induces better responses in melanoma patients
Surgical removal of metastatic melanoma helped patients live more than twice as long as those who receive only medical therapy, according to the results of a new study.
Newly approved immunotherapy transforms lung cancer treatment
The breakthrough immunotherapy Keytruda got approved by the U.S. FDA to treat patients with advanced non-small cell lung cancer.
Weight training: a key to long-term health in breast cancer survivors
Breast cancer survivors improved their physical functionality lost due to chemotherapy when participated at a six-month weight training program, a new study shows.
Combination immunotherapy for advanced melanoma approved by the FDA
U.S. regulators approved the combination of the immunotherapies nivolumab and ipilimumab for the treatment of patients with melanoma without a BRAF mutation.
New combination therapy boosts survival in melanoma patients
Patients of advanced BRAF-mutant melanoma survived longer when treated with a combination of the targeted therapies dabrafenib and trametinib.
New drug brings hope to patients with rare cancers
New drug Afinitor® (everolimus) reduced the disease progression risk in patients with advanced, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin.
Prenatal exposure to cancer treatment: is it dangerous for the baby?
Children born to mothers affected by cancer had no significant differences in mental development compared to children from the general population.
New immunotherapy shows positive results in bladder and lung cancer
Roche’s new immune-system boosting drug, atezolizumab, improved patient outcomes for lung and bladder cancer patients, according to separate phase 2 trials.